deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT03099499

Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer

A Phase 2 Study of Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer

Sponsor: Fox Chase Cancer Center

Conditions Endometrial Cancer
Interventions ONC201
Updated 14 times since 2017 Last updated: Dec 20, 2024 Started: Jun 8, 2017 Primary completion: Sep 9, 2020 Completion: Sep 9, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Slow accrual

Other terminated trials from Fox Chase Cancer Center

See all terminations from Fox Chase Cancer Center

Other Endometrial Cancer trials with similar outcome

Browse all Endometrial Cancer trials

A PHASE2 clinical study on Endometrial Cancer, this trial is terminated or withdrawn. The trial is conducted by Fox Chase Cancer Center and has accumulated 14 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~May 2017 – ~Aug 2017 · 3 months · monthly snapshot~Aug 2017 – ~Jun 2018 · 10 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~May 2019 · 9 months · monthly snapshot~May 2019 – ~May 2020 · 12 months · monthly snapshot~May 2020 – ~Jan 2021 · 8 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Jun 2022 · 12 months · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Feb 2024 · 17 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshot~Jan 2025 – present · 18 months · monthly snapshot

Change History

14 versions recorded

  1. Jan 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Jan 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Feb 2024 — Jul 2024 [monthly]

    Terminated PHASE2

    Status: Suspended → Terminated

  5. Sep 2022 — Feb 2024 [monthly]

    Suspended PHASE2

▶ Show 9 earlier versions

  1. Jun 2022 — Sep 2022 [monthly]

    Suspended PHASE2

  2. Jun 2021 — Jun 2022 [monthly]

    Suspended PHASE2

    Status: Recruiting → Suspended

  3. Jan 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

  4. May 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  5. May 2019 — May 2020 [monthly]

    Recruiting PHASE2

  6. Aug 2018 — May 2019 [monthly]

    Recruiting PHASE2

  7. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  8. Aug 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  9. May 2017 — Aug 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Fox Chase Cancer Center
  • Oncoceutics, Inc.
Data source: Fox Chase Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations